Mariner’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Mariner’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,073	Closed	-$241K	–	771
2019 Q4	$241K	Sell	10,073 -502	-5%	-$13.8K	﹤0.01%	686
2019 Q3	$284K	Buy	10,575 +1,613	+18%	+$45.3K	﹤0.01%	651
2019 Q2	$243K	Buy	+8,962	New	+$281K	﹤0.01%	966

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Mariner's PTLA Position: Q1 2020 in Review

Mariner sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 10,073 shares — an estimated $241K sold.

Mariner first reported a position in PTLA in Q2 2019 and held it in 3 quarters. The position peaked at $284K in Q3 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Mariner reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Mariner sold 10,073 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $241K.
Mariner first reported a position in Portola Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
Mariner's Portola Pharmaceuticals, Inc. position peaked at $284K in Q3 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Mariner's 13F filing for Q1 2020, filed 14 May 2020.